ATE280572T1 - Verabreichung von arzneistoffen im unteren verdauungstrakt - Google Patents

Verabreichung von arzneistoffen im unteren verdauungstrakt

Info

Publication number
ATE280572T1
ATE280572T1 AT96919237T AT96919237T ATE280572T1 AT E280572 T1 ATE280572 T1 AT E280572T1 AT 96919237 T AT96919237 T AT 96919237T AT 96919237 T AT96919237 T AT 96919237T AT E280572 T1 ATE280572 T1 AT E280572T1
Authority
AT
Austria
Prior art keywords
weight
drug
composition
administration
colon
Prior art date
Application number
AT96919237T
Other languages
English (en)
Inventor
David R Friend
David Wong
Original Assignee
Watson Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,974 external-priority patent/US5656294A/en
Application filed by Watson Lab Inc filed Critical Watson Lab Inc
Application granted granted Critical
Publication of ATE280572T1 publication Critical patent/ATE280572T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT96919237T 1995-06-07 1996-06-07 Verabreichung von arzneistoffen im unteren verdauungstrakt ATE280572T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/486,974 US5656294A (en) 1995-06-07 1995-06-07 Colonic delivery of drugs
US08/602,611 US5811388A (en) 1995-06-07 1996-02-16 Delivery of drugs to the lower GI tract
PCT/US1996/009609 WO1996040078A1 (en) 1995-06-07 1996-06-07 Delivery of drugs to the lower gi tract

Publications (1)

Publication Number Publication Date
ATE280572T1 true ATE280572T1 (de) 2004-11-15

Family

ID=27048854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919237T ATE280572T1 (de) 1995-06-07 1996-06-07 Verabreichung von arzneistoffen im unteren verdauungstrakt

Country Status (11)

Country Link
US (1) US5811388A (de)
EP (1) EP0831791B1 (de)
JP (1) JPH11507357A (de)
AT (1) ATE280572T1 (de)
AU (1) AU6163096A (de)
CA (1) CA2224170A1 (de)
DE (1) DE69633721T2 (de)
DK (1) DK0831791T3 (de)
ES (1) ES2231815T3 (de)
PT (1) PT831791E (de)
WO (1) WO1996040078A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US6162464A (en) * 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
AU758501B2 (en) * 1997-09-26 2003-03-20 Tillotts Pharma Ag Pharmaceutical composition for the treatment of inflammatory bowel disease
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6251863B1 (en) 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
EP2266542A3 (de) * 1998-10-01 2013-07-31 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter Wirkstofffreisetzung
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2003024427A1 (en) * 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
WO2002072033A2 (en) * 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
CA2459014C (en) * 2001-09-14 2010-08-10 Scolr, Inc. Amino acid modulated extended release dosage form
EP1443912B1 (de) * 2001-10-12 2007-08-29 Elan Pharma International Limited Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US7887838B2 (en) 2002-01-18 2011-02-15 Banner Pharmacaps, Inc. Non-gelatin film and method and apparatus for producing same
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
DE60330161D1 (de) * 2002-08-29 2009-12-31 Activbiotics Pharma Llc Rifalazil zur behandlung von infektionen mit clostridium difficile
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
AU2003293833B2 (en) * 2002-12-12 2009-10-01 Covis Pharma B.V. Combination medicament
US20040142968A1 (en) * 2003-01-17 2004-07-22 Donald Price Method and kit for treating lower bowel pain
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
US20050013847A1 (en) * 2003-04-14 2005-01-20 Fmc Corporation Delivery systems of homogeneous, thermoreversible alginate films
US20050048185A1 (en) * 2003-04-14 2005-03-03 Fmc Corporation Delivery systems of homogeneous, thermoreversible low viscosity polymannan gum films
US20050019295A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
US20050008677A1 (en) * 2003-04-14 2005-01-13 Fmc Corporation Delivery system of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
US7816341B2 (en) * 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
US20050019294A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible alginate films and soft capsules made therefrom
JP2007525451A (ja) * 2003-04-14 2007-09-06 エフ　エム　シー　コーポレーション 均一かつ熱可逆性アルギネートフィルムの伝達システム
MXPA05011446A (es) 2003-04-24 2006-05-31 Jagotec Ag Tableta con liberacion retardada con geometria de nucleo definida.
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
EP1670481B1 (de) * 2003-09-15 2010-08-04 Nycomed GmbH Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
AP2006003585A0 (en) * 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
US20050118267A1 (en) 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
DE602004030931D1 (de) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
EP1740188A1 (de) * 2004-04-20 2007-01-10 Altana Pharma AG Verwendung von ciclesonid zur behandlung von atemwegserkrankungen eines rauchenden patienten
DE102004043863A1 (de) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
AU2011232809B2 (en) * 2004-09-10 2014-03-20 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
WO2006027266A1 (en) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EA015304B1 (ru) 2006-08-03 2011-06-30 Нитек Фарма Аг Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2298321A1 (de) * 2009-08-26 2011-03-23 Nordic Pharma Neuartige pharmazeutische Zusammensetzungen zur Behandlung von IBD
AU2011280039B2 (en) 2010-06-30 2014-08-07 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AP2015008579A0 (en) 2013-02-05 2015-07-31 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
AU2016359494B2 (en) 2015-11-24 2021-01-07 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10472366B2 (en) 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
US10233174B2 (en) 2017-05-23 2019-03-19 Theravance Biopharma R&D Ip, Llc Thiocarbamate prodrugs of tofacitinib
BR112019024509A2 (pt) 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7710850B2 (ja) 2017-12-29 2025-07-22 ラクソン メディカル アーゲー 薬物送達システム
EP3802504B1 (de) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3810084A1 (de) 2018-06-20 2021-04-28 Albireo AB Pharmazeutische formulierung von odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
DK3921028T3 (da) 2019-02-06 2023-01-23 Albireo Ab Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
JP7696897B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN116157389B (zh) 2020-08-03 2026-02-10 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022254456A1 (en) * 2021-06-01 2022-12-08 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
DE2130545A1 (de) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmazeutischer Formkoerper
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4894233A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for decongestants
EP0222883A1 (de) * 1985-05-15 1987-05-27 Riker Laboratories, Inc. Theophyllinarzneimittel mit verzögerter freigabe sowie verfahren zu deren herstellung
SE8601563D0 (sv) * 1986-04-08 1986-04-08 Carbomatrix Ab Matrismaterial, forfarande for framstellning derav och anvendning derav
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5466469A (en) * 1988-06-28 1995-11-14 Cibus Pharmaceutical, Inc. Granular drug delivery system
CA1334379C (en) * 1987-11-24 1995-02-14 James William Mcginity Method for preparing a solid sustained release form of a functionally active composition
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US5445826A (en) * 1988-06-28 1995-08-29 Cibus Pharmaceutical, Inc. Delivery system containing a gel-forming dietary fiber and a drug
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
JP2683391B2 (ja) * 1988-11-30 1997-11-26 日清製粉株式会社 小麦ふすまからのヘミセルロースを基材とする徐放性組成物
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
AU660147B2 (en) * 1990-05-04 1995-06-15 Perio Products Ltd. Colonic drug delivery system
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
FR2667242B1 (fr) * 1990-09-28 1994-11-25 Rhone Poulenc Sante Nouvelles formes orales a liberation prolongee avec un temps de latence au niveau stomacal amoindri.
EP0481240B1 (de) * 1990-10-18 1996-12-11 Basf Aktiengesellschaft Galactomannanderivate zur Umhüllung oder Einbettung von Arzneimittelwirkstoffen
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE9015551U1 (de) * 1990-11-14 1992-03-12 Röhm GmbH, 6100 Darmstadt Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccarid
EP0676967A4 (de) * 1992-12-30 1996-10-02 Fmc Corp Leicht verfügbarer hilfsstoff zur verzögerten freisetzung auf der basis von konjac glukomannan.
JPH10509981A (ja) * 1994-12-01 1998-09-29 サイバス ファーマシューティカル，インコーポレイティド 高等植物から得られうる粉末状親水コロイドゴムを用いる持効性薬剤送出
CA2205442C (en) * 1994-12-01 2003-01-21 David R. Friend Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs

Also Published As

Publication number Publication date
DE69633721T2 (de) 2005-12-22
PT831791E (pt) 2005-02-28
CA2224170A1 (en) 1996-12-19
EP0831791A1 (de) 1998-04-01
JPH11507357A (ja) 1999-06-29
DK0831791T3 (da) 2005-01-31
US5811388A (en) 1998-09-22
EP0831791A4 (de) 1998-08-26
EP0831791B1 (de) 2004-10-27
AU6163096A (en) 1996-12-30
DE69633721D1 (de) 2004-12-02
WO1996040078A1 (en) 1996-12-19
ES2231815T3 (es) 2005-05-16

Similar Documents

Publication Publication Date Title
ATE280572T1 (de) Verabreichung von arzneistoffen im unteren verdauungstrakt
NO940376L (no) Doseringsanordning for avgivelse av medikament over et tidsrom med kort varighet
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
DE69532678D1 (de) Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende Arzneimittel
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
DZ1884A1 (fr) Formulations orales liquides d'alendronate.
JP2005515966A5 (de)
NO895167D0 (no) Fremgangsmaate for behandling av tannrotsykdom ved vedvarende avgivelse av et farmasoeytisk middel til crevikularlommen, stoffblanding for dette og apparat for administrering derav.
ATE145819T1 (de) Inhalierbare arzneimittel
MY125662A (en) Pharmaceutical formulations containing darifenacin
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
NO890194L (no) Galenisk middel.
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
JPS61183220A (ja) 鎮痛性を有する医薬組成物
JP2002540148A5 (de)
JP2003500446A (ja) メラトニンの治療的使用法
CA1306950C (en) Buccal administration of estrogens
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
MY100780A (en) Azumolene dosage form.
JP2000500159A (ja) メラトニンと組み合わせた鎮痛剤
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
JPH01279818A (ja) 白髪黒化剤
SU449724A1 (ru) Отхаркивающее средство "мукалтин'
Jalava et al. Concentration of carprofen in the serum and the synovial fluid in rheumatoid arthritis patients

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831791

Country of ref document: EP

REN Ceased due to non-payment of the annual fee